2026-01-07 09:16
We are advised by Arkbio that journalists and other readers should disregard the news release, Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD, issued on Jan. 6, 2026 by Arkbio over PR Newswire, as the release contained inappropriate information.
source: Arkbio
【你點睇？】美國最高法院裁定特朗普關稅違法，你認為對市場有何影響？► 立即投票
上一篇新聞︰2026-01-07 09:30 亞盛醫藥BTK降解劑APG-3288的新藥臨床申請（IND）獲美國FDA許可
下一篇新聞︰2026-01-07 09:13 擷發科技在2026年CES上重點展示AIVO邊緣AI平台，助力在交通安全、農業及自主系統領域實現可擴展部署
2026-01-07 10:00 adjoe Enters Strategic Partnership with LINE to Redefine Monetization Through Mobile Gaming Offerwalls
2026-01-07 10:00 Panduit Announces Key Executive Appointments to Support Strategic Growth and Innovation
2026-01-07 10:00 adjoe 攜手 LINE 打造「邊玩邊賺」的激勵廣告新模式，推動用戶增長新動力
2026-01-07 09:00 晶泰科技賦能國內首個「AI + RNA」小分子創新藥獲批臨床，ReviR溪礫科技實現罕見病首創新藥突破
